Leversense is commercializing an innovative new method for in vitro diagnostics technology. The technology, licensed from Drexel University, is a solid-state electromechanical sensor technology used to detect protein, nucleic acid and pathogen disease indicators. Ben Franklin Technology Partners of Southeastern PA has also invested $500,000 in the company.
NTI: Signs of Success
NTI research programs have been extremely successful at publishing in peer-reviewed journals, resulting in more than 820 articles.
In addition, NTI researchers have been awarded more than 200 federal grants totaling more than $150 million.